USSTOCK.TODAY
Market Closed
Log in Sign up

MaxCyte Announces Akron Bio Acquisition and Third Quarter Revenue Growth

The Motley Fool +1 · ·by G4L

MXCT
MXCT MaxCyte Inc
$1.13 -13.08%
View chart & analysis →
  1. 1MaxCyte has agreed to acquire Akron Bio for $151.8 million.
  2. 2MaxCyte core revenue grew 27% in the third quarter to reach $10.2 million.
  3. 3The combined entity aims for an annual cash burn of less than $10 million in 2027.

So what's the key point?

MaxCyte has decided to acquire Akron Bio. Third quarter revenue reached $10.2 million.

Source The Motley Fool +1 · View original ↗

Related 3-line summaries

Lightwave Logic shifts mass production start date to 2028 The Motley Fool +1 · 23m agoSonos to Drive Revenue Growth and Profitability Improvement in FY2026 The Motley Fool +1 · 23m agoArista Networks reports 58.5% growth with $3.66 billion in Q3 revenue The Motley Fool +1 · 28m ago
Today's 5 AI picks, all free
Nothing hidden: past picks and how they did against the S&P 500.
See today's picks →
← Back to news